Seattle doctor developing treatment for sickest Coronavirus patients

Dr. Steven Quay, CEO of Atossa Therapeutics in Seattle, is preparing a drug combination called H-NAC for a clinical trial targeting COVID-19 patients on ventilators, aiming to reduce the high fatality rate associated with their usage. The drug, administered through a side port on the ventilator, forms a coating over the virus’s replication mechanisms, potentially rendering it ineffective. Quay emphasizes the need for caution in reopening the economy amidst protests, suggesting at least another two weeks to ensure safety. Plans for reopening, including prioritizing residential construction and auto sales, are being developed, with leaders urging readiness to reopen based on virus trends.

Full article here on Kiro 7.

SEATTLE — The fatality rate for COVID-19 victims on ventilators has been 50% or higher.

So, at Atossa Therapeutics in Seattle, Dr. Steven Quay is getting a drug combination ready for a clinical trial in a hard-hit hospital back east.

“There’s a side port on the ventilator where you can put medication for these patients … basically they can breathe a mist while they are on the ventilator and the goal is to get them off the ventilator and once you are off the ventilator you’ll have an improved clinical course.

Quay is CEO of Seattle’s Atossa Therapeutics. He’s says he’s invented seven FDA approved drugs for other illnesses.

Called H-NAC, the drug would put a coating over the parts of the virus that help them replicate so quickly, rendering it ineffective, similar to what a vaccine does.

“We want to teach the immune system to coat the virus with antibodies, I’m coating the virus … with these two already FDA approved drugs,” he said.


Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

In a recent conversation on The Vince Coglianese Show, Dr. Steven Quay shares his thoughts on various aspects of the COVID-19 pandemic, shedding light on critical issues ranging from the origins of the virus to the trust deficit in the medical community.

The recent House Committee testimony has stirred up discussions regarding public health, vaccination, and trust in government agencies. Dr. Quay breaks down Dr. Fuaci's testimony with Rich Valdés on this 2 hour podcast.

Dr. Steven Quay is featured on NewsNation to discuss a new medical breakthrough cancer pill which early research suggests it destroys all solid tumors. Dr. Quay says it’s a “highly significant finding”.